Cargando…
Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
OBJECTIVE: To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture. Secondary objectives were to quantify functional outcome impairment and describ...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131055/ https://www.ncbi.nlm.nih.gov/pubmed/36053661 http://dx.doi.org/10.1136/bmjpo-2022-001428 |
_version_ | 1784713104472408064 |
---|---|
author | Ali, Samina Gourlay, Katie Yukseloglu, Aran Rosychuk, Rhonda J Ortiz, Silvia Watts, Rick Johnson, David W Carleton, Bruce Le May, Sylvie Drendel, Amy L |
author_facet | Ali, Samina Gourlay, Katie Yukseloglu, Aran Rosychuk, Rhonda J Ortiz, Silvia Watts, Rick Johnson, David W Carleton, Bruce Le May, Sylvie Drendel, Amy L |
author_sort | Ali, Samina |
collection | PubMed |
description | OBJECTIVE: To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture. Secondary objectives were to quantify functional outcome impairment and describe demographic and clinical characteristics associated with AEs. DESIGN: Observational cohort study. SETTING: Paediatric emergency department. PATIENTS: Patients (n=240) aged 4–16 years diagnosed with an acute fracture. INTERVENTION: Prescribed either ibuprofen (n=179) or oxycodone (n=61) for pain. MAIN OUTCOME MEASURES: Families were called for the first 3 days after discharge to report the presence and intensity of AEs and their child’s functional outcomes (ability to eat, sleep, play or attend school). RESULTS: On day 1, children using oxycodone were more likely to report any AE (χ(2)(1)=13.5, p<0.001), nausea (χ(2)(1)=17.0, p<0.001), vomiting (χ(2)(1)=11.2, p<0.001), drowsiness (χ(2)(1)=13.7, p<0.001), constipation (χ(2)(1)=8.9, p=0.003) and dizziness (χ(2)(1)=19.1, p<0.001), compared with those using ibuprofen. Children receiving oxycodone reported greater severity of abdominal pain (oxycodone: mean 5.4 SD 3.1; ibuprofen mean 2.5 SD 1.4, F(1)(13)=6.5, p=0.02) on day 1 and worse intensity of constipation (oxycodone: mean 4.9 SD 2.1; ibuprofen mean 3.2 SD 2.2, F(1)(33)=4.5, p=0.04) over all 3 days. Use of oxycodone was associated with an increased odds of experiencing an AE on day 1 (OR=1.31 (95% CI 1.13 to 1.52)). Higher pain scores (OR=1.50 (95% CI 1.12 to 2.01)), lower extremity fracture (OR=1.25 (95% CI 1.07 to 1.47)) and undergoing ED sedation (OR=1.16 (95% CI 1.01 to 1.34)) were associated with missing school. Higher pain scores (OR=1.50 (95% CI 1.14 to 1.97)) and lower extremity fractures (OR=1.23 (95% CI 1.07 to 1.43)) were also associated with less play. CONCLUSIONS: Oxycodone is associated with more frequent AEs overall, higher intensity gastrointestinal AEs and greater functional limitations compared with ibuprofen. Lower extremity fractures cause more functional limitations than upper extremity fractures. Clinicians should consider these differences when providing fracture pain care for children. |
format | Online Article Text |
id | pubmed-9131055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91310552022-06-09 Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study Ali, Samina Gourlay, Katie Yukseloglu, Aran Rosychuk, Rhonda J Ortiz, Silvia Watts, Rick Johnson, David W Carleton, Bruce Le May, Sylvie Drendel, Amy L BMJ Paediatr Open Pain OBJECTIVE: To quantify the frequency and intensity of adverse events (AEs), commonly known as side effects, experienced by children receiving either ibuprofen or oxycodone for pain management following an acute fracture. Secondary objectives were to quantify functional outcome impairment and describe demographic and clinical characteristics associated with AEs. DESIGN: Observational cohort study. SETTING: Paediatric emergency department. PATIENTS: Patients (n=240) aged 4–16 years diagnosed with an acute fracture. INTERVENTION: Prescribed either ibuprofen (n=179) or oxycodone (n=61) for pain. MAIN OUTCOME MEASURES: Families were called for the first 3 days after discharge to report the presence and intensity of AEs and their child’s functional outcomes (ability to eat, sleep, play or attend school). RESULTS: On day 1, children using oxycodone were more likely to report any AE (χ(2)(1)=13.5, p<0.001), nausea (χ(2)(1)=17.0, p<0.001), vomiting (χ(2)(1)=11.2, p<0.001), drowsiness (χ(2)(1)=13.7, p<0.001), constipation (χ(2)(1)=8.9, p=0.003) and dizziness (χ(2)(1)=19.1, p<0.001), compared with those using ibuprofen. Children receiving oxycodone reported greater severity of abdominal pain (oxycodone: mean 5.4 SD 3.1; ibuprofen mean 2.5 SD 1.4, F(1)(13)=6.5, p=0.02) on day 1 and worse intensity of constipation (oxycodone: mean 4.9 SD 2.1; ibuprofen mean 3.2 SD 2.2, F(1)(33)=4.5, p=0.04) over all 3 days. Use of oxycodone was associated with an increased odds of experiencing an AE on day 1 (OR=1.31 (95% CI 1.13 to 1.52)). Higher pain scores (OR=1.50 (95% CI 1.12 to 2.01)), lower extremity fracture (OR=1.25 (95% CI 1.07 to 1.47)) and undergoing ED sedation (OR=1.16 (95% CI 1.01 to 1.34)) were associated with missing school. Higher pain scores (OR=1.50 (95% CI 1.14 to 1.97)) and lower extremity fractures (OR=1.23 (95% CI 1.07 to 1.43)) were also associated with less play. CONCLUSIONS: Oxycodone is associated with more frequent AEs overall, higher intensity gastrointestinal AEs and greater functional limitations compared with ibuprofen. Lower extremity fractures cause more functional limitations than upper extremity fractures. Clinicians should consider these differences when providing fracture pain care for children. BMJ Publishing Group 2022-05-23 /pmc/articles/PMC9131055/ /pubmed/36053661 http://dx.doi.org/10.1136/bmjpo-2022-001428 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Pain Ali, Samina Gourlay, Katie Yukseloglu, Aran Rosychuk, Rhonda J Ortiz, Silvia Watts, Rick Johnson, David W Carleton, Bruce Le May, Sylvie Drendel, Amy L Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
title | Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
title_full | Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
title_fullStr | Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
title_full_unstemmed | Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
title_short | Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
title_sort | quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study |
topic | Pain |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131055/ https://www.ncbi.nlm.nih.gov/pubmed/36053661 http://dx.doi.org/10.1136/bmjpo-2022-001428 |
work_keys_str_mv | AT alisamina quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT gourlaykatie quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT yukselogluaran quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT rosychukrhondaj quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT ortizsilvia quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT wattsrick quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT johnsondavidw quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT carletonbruce quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT lemaysylvie quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy AT drendelamyl quantifyingtheintensityofadverseeventswithibuprofenandoxycodoneanobservationalcohortstudy |